Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI-88 in advanced malignancies and melanoma
NCT00073892Phase 2Completed
- Sponsor
- Cellxpert Biotechnology Corp.
- Start
- Jan 2004
- Primary completion
- Nov 2005
- Modality
- Bivalent/Multivalent Binders
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Muparfostat in solid tumor and melanoma, sponsored by Cellxpert Biotechnology Corp. Primary endpoints: Maximum Tolerated Dose, Safety and Tolerability and 3 more. Started Jan 2004; status: completed.
02
Drugs
Muparfostat
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT00073892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073892.